P24.07 Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

Saved in:
Bibliographic Details
Published inJournal of thoracic oncology Vol. 16; no. 3; p. S380
Main Authors Haakensen, V., Nowak, A., Ellingsen, E., Grundberg, O., Farooqi, S., Mcculloch, T., Cedres, S., Bjaanæs, M., Helland, Å.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.03.2021
Online AccessGet full text

Cover

More Information
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2021.01.616